focus -WSS

focus

author：entertainment 2025-09-28 16:35:07 - browse：4

Vir Biotechnology said Thursday that a long-acting antibody drug designed to protect healthy individuals from influenza A failed to do so in a nearly 3,000-person clinical trial.

Volunteers who received the highest dose of the drug, known as VIR-2482, were only 16% less likely than the placebo group to develop symptomatic influenza A infections, as defined by trial criteria, over a seven-month period. The difference was not statistically significant.

The results are a setback in broader efforts to develop better protective measures against both seasonal and potential pandemic influenza strains. In the short term, Vir and outside experts hoped VIR-2482 could provide additional annual protection for at-risk groups like older adults, as flu vaccines are often only modestly effective.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medical records are filled with copy
Next article： STAT Virtual Event: How to Increase Diversity in Clinical Trials

hotspot

WSS

A fraught question for the kids of Alzheimer’s: Is it coming for us?

FDA seeks to regulate lab

Why do women spend more than men on medical expenses?

Biogen shutters digital health group, ends Apple study, in cost cutting move

Researchers use wearables data and AI to predict preterm birth risk

Data show record exodus of life scientists from academia

explore

focus

Wikipedia

Affirmative action in medical school literally saved lives

Health tech startups drop sharply from 2021 highs

FDA approval of Sarepta Duchenne genetic therapy gives me hope

A revolution in caring for preterm infants

Supreme Court strikes down use of affirmative action

Massive project maps cells in human brain in unprecedented detail

Supreme Court strikes down use of affirmative action

How the Dana

Guidelines to prevent youth baseball injuries need more muscle

Akero's treatment for NASH falls short in cirrhosis study

knowledge

Cigna to pay $172 million to settle Medicare Advantage fraud probe

How clinical AI models' predictive power can degrade over time

Data show record exodus of life scientists from academia

Cancer cells are shown to suck energy source from immune cells

Nick Jonas talks about managing diabetes along with his career

FDA seeks to regulate lab

knowledge

hotspot

explore

explore